
    
      The duration of the study for each patient will include an up to 4-week screening phase,
      21-day study treatment cycles, an end of treatment visit and a follow-up period 30 days after
      the last infusion of ombrabulin. The patient will continue treatment until disease
      progression, unacceptable toxicity, patient's refusal of further treatment.
    
  